Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

KEY TAKEAWAYS Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

Ligelizumab is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody that shows promise for treating chronic hives that arise spontaneously. Sporadic hives that occur often, last anywhere ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...